“…Another real-world study revealed the efficacy of eltrombopag in providing a rapid, sustained response that improves haematopoietic function in PGF patients [ 44 ]. Avatrombopag [ 45 , 46 ], hetrombopag [ 47 ], and romiplostim [ 48 ] have all been reported to improve platelet engraftment post-HSCT. A recent systematic review and meta-analysis has concluded that eltrombopag could provide an effective treatment option for PGF with an acceptable toxicity profile [ 49 ].…”